c-Met inhibitors are a class of small molecules that inhibit the enzymatic activity of the c-Met tyrosine kinase, the receptor of hepatocyte growth factor/scatter factor (HGF/SF).
The global C-MET & HGF Inhibitors market size was valued at US$ 2973 million in 2023 and is forecast to a readjusted size of USD 12720 million by 2030 with a CAGR of 23.3% during review period.
There are three kinds of C-MET / HGF Inhibitors, which are Cabozantinib, Crizotinib and Others. Cabozantinib hold the largest share of the C-MET / HGF Inhibitors market, with a revenue market share nearly 66% in 2019.
C-MET / HGF Inhibitors is sold through Hospitals and Drugs Store. The most proportion of C-MET / HGF Inhibitors is sold through Hospitals, and the market share in 2019 is about 77%.
North America is the largest consumption place, with a consumption market share nearly 60% in 2019. Following North America, Europe is the second largest consumption place with the consumption market share of about 34%.
Shandong Exelixis, Ipsen, Pfizer, etc. are the leader of the industry, and top 3 players hold about 100% revenue market share.
This report is a detailed and comprehensive analysis for global C-MET & HGF Inhibitors market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2024, are provided.
Key Features:
Global C-MET & HGF Inhibitors market size and forecasts, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2019-2030
Global C-MET & HGF Inhibitors market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2019-2030
Global C-MET & HGF Inhibitors market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2019-2030
Global C-MET & HGF Inhibitors market shares of main players, shipments in revenue ($ Million), sales quantity (K Units), and ASP (US$/Unit), 2019-2024
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for C-MET & HGF Inhibitors
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global C-MET & HGF Inhibitors market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Exelixis, Ipsen, Pfizer, Novartis, Takeda, Merck KGaA, Merck, Daiichi Sankyo, GSK, Bristol-Myers Squibb(BMS), etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
麻豆原创 Segmentation
C-MET & HGF Inhibitors market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
麻豆原创 segment by Type
Cabozantinib
Crizotinib
Others
麻豆原创 segment by Application
Hospital
Drug Store
Major players covered
Exelixis
Ipsen
Pfizer
Novartis
Takeda
Merck KGaA
Merck
Daiichi Sankyo
GSK
Bristol-Myers Squibb(BMS)
Roche
AVEO Pharmaceuticals
Amgen
AstraZeneca
Mirati Therapeutics
Eli Lilly
Johnson & Johnson
Eisai
Hutchison MediPharma
Kringle Pharmaceuticals
麻豆原创 segment by region, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe C-MET & HGF Inhibitors product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of C-MET & HGF Inhibitors, with price, sales quantity, revenue, and global market share of C-MET & HGF Inhibitors from 2019 to 2024.
Chapter 3, the C-MET & HGF Inhibitors competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the C-MET & HGF Inhibitors breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2019 to 2030.
Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2019 to 2030.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2019 to 2024.and C-MET & HGF Inhibitors market forecast, by regions, by Type, and by Application, with sales and revenue, from 2025 to 2030.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of C-MET & HGF Inhibitors.
Chapter 14 and 15, to describe C-MET & HGF Inhibitors sales channel, distributors, customers, research findings and conclusion.
Please Note - This is an on demand report and will be delivered in 2 business days (48 Hours) post payment.
1 麻豆原创 Overview
1.1 Product Overview and Scope
1.2 麻豆原创 Estimation Caveats and Base Year
1.3 麻豆原创 Analysis by Type
1.3.1 Overview: Global C-MET & HGF Inhibitors Consumption Value by Type: 2019 Versus 2023 Versus 2030
1.3.2 Cabozantinib
1.3.3 Crizotinib
1.3.4 Others
1.4 麻豆原创 Analysis by Application
1.4.1 Overview: Global C-MET & HGF Inhibitors Consumption Value by Application: 2019 Versus 2023 Versus 2030
1.4.2 Hospital
1.4.3 Drug Store
1.5 Global C-MET & HGF Inhibitors 麻豆原创 Size & Forecast
1.5.1 Global C-MET & HGF Inhibitors Consumption Value (2019 & 2023 & 2030)
1.5.2 Global C-MET & HGF Inhibitors Sales Quantity (2019-2030)
1.5.3 Global C-MET & HGF Inhibitors Average Price (2019-2030)
2 Manufacturers Profiles
2.1 Exelixis
2.1.1 Exelixis Details
2.1.2 Exelixis Major Business
2.1.3 Exelixis C-MET & HGF Inhibitors Product and Services
2.1.4 Exelixis C-MET & HGF Inhibitors Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.1.5 Exelixis Recent Developments/Updates
2.2 Ipsen
2.2.1 Ipsen Details
2.2.2 Ipsen Major Business
2.2.3 Ipsen C-MET & HGF Inhibitors Product and Services
2.2.4 Ipsen C-MET & HGF Inhibitors Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.2.5 Ipsen Recent Developments/Updates
2.3 Pfizer
2.3.1 Pfizer Details
2.3.2 Pfizer Major Business
2.3.3 Pfizer C-MET & HGF Inhibitors Product and Services
2.3.4 Pfizer C-MET & HGF Inhibitors Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.3.5 Pfizer Recent Developments/Updates
2.4 Novartis
2.4.1 Novartis Details
2.4.2 Novartis Major Business
2.4.3 Novartis C-MET & HGF Inhibitors Product and Services
2.4.4 Novartis C-MET & HGF Inhibitors Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.4.5 Novartis Recent Developments/Updates
2.5 Takeda
2.5.1 Takeda Details
2.5.2 Takeda Major Business
2.5.3 Takeda C-MET & HGF Inhibitors Product and Services
2.5.4 Takeda C-MET & HGF Inhibitors Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.5.5 Takeda Recent Developments/Updates
2.6 Merck KGaA
2.6.1 Merck KGaA Details
2.6.2 Merck KGaA Major Business
2.6.3 Merck KGaA C-MET & HGF Inhibitors Product and Services
2.6.4 Merck KGaA C-MET & HGF Inhibitors Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.6.5 Merck KGaA Recent Developments/Updates
2.7 Merck
2.7.1 Merck Details
2.7.2 Merck Major Business
2.7.3 Merck C-MET & HGF Inhibitors Product and Services
2.7.4 Merck C-MET & HGF Inhibitors Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.7.5 Merck Recent Developments/Updates
2.8 Daiichi Sankyo
2.8.1 Daiichi Sankyo Details
2.8.2 Daiichi Sankyo Major Business
2.8.3 Daiichi Sankyo C-MET & HGF Inhibitors Product and Services
2.8.4 Daiichi Sankyo C-MET & HGF Inhibitors Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.8.5 Daiichi Sankyo Recent Developments/Updates
2.9 GSK
2.9.1 GSK Details
2.9.2 GSK Major Business
2.9.3 GSK C-MET & HGF Inhibitors Product and Services
2.9.4 GSK C-MET & HGF Inhibitors Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.9.5 GSK Recent Developments/Updates
2.10 Bristol-Myers Squibb(BMS)
2.10.1 Bristol-Myers Squibb(BMS) Details
2.10.2 Bristol-Myers Squibb(BMS) Major Business
2.10.3 Bristol-Myers Squibb(BMS) C-MET & HGF Inhibitors Product and Services
2.10.4 Bristol-Myers Squibb(BMS) C-MET & HGF Inhibitors Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.10.5 Bristol-Myers Squibb(BMS) Recent Developments/Updates
2.11 Roche
2.11.1 Roche Details
2.11.2 Roche Major Business
2.11.3 Roche C-MET & HGF Inhibitors Product and Services
2.11.4 Roche C-MET & HGF Inhibitors Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.11.5 Roche Recent Developments/Updates
2.12 AVEO Pharmaceuticals
2.12.1 AVEO Pharmaceuticals Details
2.12.2 AVEO Pharmaceuticals Major Business
2.12.3 AVEO Pharmaceuticals C-MET & HGF Inhibitors Product and Services
2.12.4 AVEO Pharmaceuticals C-MET & HGF Inhibitors Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.12.5 AVEO Pharmaceuticals Recent Developments/Updates
2.13 Amgen
2.13.1 Amgen Details
2.13.2 Amgen Major Business
2.13.3 Amgen C-MET & HGF Inhibitors Product and Services
2.13.4 Amgen C-MET & HGF Inhibitors Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.13.5 Amgen Recent Developments/Updates
2.14 AstraZeneca
2.14.1 AstraZeneca Details
2.14.2 AstraZeneca Major Business
2.14.3 AstraZeneca C-MET & HGF Inhibitors Product and Services
2.14.4 AstraZeneca C-MET & HGF Inhibitors Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.14.5 AstraZeneca Recent Developments/Updates
2.15 Mirati Therapeutics
2.15.1 Mirati Therapeutics Details
2.15.2 Mirati Therapeutics Major Business
2.15.3 Mirati Therapeutics C-MET & HGF Inhibitors Product and Services
2.15.4 Mirati Therapeutics C-MET & HGF Inhibitors Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.15.5 Mirati Therapeutics Recent Developments/Updates
2.16 Eli Lilly
2.16.1 Eli Lilly Details
2.16.2 Eli Lilly Major Business
2.16.3 Eli Lilly C-MET & HGF Inhibitors Product and Services
2.16.4 Eli Lilly C-MET & HGF Inhibitors Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.16.5 Eli Lilly Recent Developments/Updates
2.17 Johnson & Johnson
2.17.1 Johnson & Johnson Details
2.17.2 Johnson & Johnson Major Business
2.17.3 Johnson & Johnson C-MET & HGF Inhibitors Product and Services
2.17.4 Johnson & Johnson C-MET & HGF Inhibitors Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.17.5 Johnson & Johnson Recent Developments/Updates
2.18 Eisai
2.18.1 Eisai Details
2.18.2 Eisai Major Business
2.18.3 Eisai C-MET & HGF Inhibitors Product and Services
2.18.4 Eisai C-MET & HGF Inhibitors Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.18.5 Eisai Recent Developments/Updates
2.19 Hutchison MediPharma
2.19.1 Hutchison MediPharma Details
2.19.2 Hutchison MediPharma Major Business
2.19.3 Hutchison MediPharma C-MET & HGF Inhibitors Product and Services
2.19.4 Hutchison MediPharma C-MET & HGF Inhibitors Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.19.5 Hutchison MediPharma Recent Developments/Updates
2.20 Kringle Pharmaceuticals
2.20.1 Kringle Pharmaceuticals Details
2.20.2 Kringle Pharmaceuticals Major Business
2.20.3 Kringle Pharmaceuticals C-MET & HGF Inhibitors Product and Services
2.20.4 Kringle Pharmaceuticals C-MET & HGF Inhibitors Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.20.5 Kringle Pharmaceuticals Recent Developments/Updates
3 Competitive Environment: C-MET & HGF Inhibitors by Manufacturer
3.1 Global C-MET & HGF Inhibitors Sales Quantity by Manufacturer (2019-2024)
3.2 Global C-MET & HGF Inhibitors Revenue by Manufacturer (2019-2024)
3.3 Global C-MET & HGF Inhibitors Average Price by Manufacturer (2019-2024)
3.4 麻豆原创 Share Analysis (2023)
3.4.1 Producer Shipments of C-MET & HGF Inhibitors by Manufacturer Revenue ($MM) and 麻豆原创 Share (%): 2023
3.4.2 Top 3 C-MET & HGF Inhibitors Manufacturer 麻豆原创 Share in 2023
3.4.3 Top 6 C-MET & HGF Inhibitors Manufacturer 麻豆原创 Share in 2023
3.5 C-MET & HGF Inhibitors 麻豆原创: Overall Company Footprint Analysis
3.5.1 C-MET & HGF Inhibitors 麻豆原创: Region Footprint
3.5.2 C-MET & HGF Inhibitors 麻豆原创: Company Product Type Footprint
3.5.3 C-MET & HGF Inhibitors 麻豆原创: Company Product Application Footprint
3.6 New 麻豆原创 Entrants and Barriers to 麻豆原创 Entry
3.7 Mergers, Acquisition, Agreements, and Collaborations
4 Consumption Analysis by Region
4.1 Global C-MET & HGF Inhibitors 麻豆原创 Size by Region
4.1.1 Global C-MET & HGF Inhibitors Sales Quantity by Region (2019-2030)
4.1.2 Global C-MET & HGF Inhibitors Consumption Value by Region (2019-2030)
4.1.3 Global C-MET & HGF Inhibitors Average Price by Region (2019-2030)
4.2 North America C-MET & HGF Inhibitors Consumption Value (2019-2030)
4.3 Europe C-MET & HGF Inhibitors Consumption Value (2019-2030)
4.4 Asia-Pacific C-MET & HGF Inhibitors Consumption Value (2019-2030)
4.5 South America C-MET & HGF Inhibitors Consumption Value (2019-2030)
4.6 Middle East & Africa C-MET & HGF Inhibitors Consumption Value (2019-2030)
5 麻豆原创 Segment by Type
5.1 Global C-MET & HGF Inhibitors Sales Quantity by Type (2019-2030)
5.2 Global C-MET & HGF Inhibitors Consumption Value by Type (2019-2030)
5.3 Global C-MET & HGF Inhibitors Average Price by Type (2019-2030)
6 麻豆原创 Segment by Application
6.1 Global C-MET & HGF Inhibitors Sales Quantity by Application (2019-2030)
6.2 Global C-MET & HGF Inhibitors Consumption Value by Application (2019-2030)
6.3 Global C-MET & HGF Inhibitors Average Price by Application (2019-2030)
7 North America
7.1 North America C-MET & HGF Inhibitors Sales Quantity by Type (2019-2030)
7.2 North America C-MET & HGF Inhibitors Sales Quantity by Application (2019-2030)
7.3 North America C-MET & HGF Inhibitors 麻豆原创 Size by Country
7.3.1 North America C-MET & HGF Inhibitors Sales Quantity by Country (2019-2030)
7.3.2 North America C-MET & HGF Inhibitors Consumption Value by Country (2019-2030)
7.3.3 United States 麻豆原创 Size and Forecast (2019-2030)
7.3.4 Canada 麻豆原创 Size and Forecast (2019-2030)
7.3.5 Mexico 麻豆原创 Size and Forecast (2019-2030)
8 Europe
8.1 Europe C-MET & HGF Inhibitors Sales Quantity by Type (2019-2030)
8.2 Europe C-MET & HGF Inhibitors Sales Quantity by Application (2019-2030)
8.3 Europe C-MET & HGF Inhibitors 麻豆原创 Size by Country
8.3.1 Europe C-MET & HGF Inhibitors Sales Quantity by Country (2019-2030)
8.3.2 Europe C-MET & HGF Inhibitors Consumption Value by Country (2019-2030)
8.3.3 Germany 麻豆原创 Size and Forecast (2019-2030)
8.3.4 France 麻豆原创 Size and Forecast (2019-2030)
8.3.5 United Kingdom 麻豆原创 Size and Forecast (2019-2030)
8.3.6 Russia 麻豆原创 Size and Forecast (2019-2030)
8.3.7 Italy 麻豆原创 Size and Forecast (2019-2030)
9 Asia-Pacific
9.1 Asia-Pacific C-MET & HGF Inhibitors Sales Quantity by Type (2019-2030)
9.2 Asia-Pacific C-MET & HGF Inhibitors Sales Quantity by Application (2019-2030)
9.3 Asia-Pacific C-MET & HGF Inhibitors 麻豆原创 Size by Region
9.3.1 Asia-Pacific C-MET & HGF Inhibitors Sales Quantity by Region (2019-2030)
9.3.2 Asia-Pacific C-MET & HGF Inhibitors Consumption Value by Region (2019-2030)
9.3.3 China 麻豆原创 Size and Forecast (2019-2030)
9.3.4 Japan 麻豆原创 Size and Forecast (2019-2030)
9.3.5 South Korea 麻豆原创 Size and Forecast (2019-2030)
9.3.6 India 麻豆原创 Size and Forecast (2019-2030)
9.3.7 Southeast Asia 麻豆原创 Size and Forecast (2019-2030)
9.3.8 Australia 麻豆原创 Size and Forecast (2019-2030)
10 South America
10.1 South America C-MET & HGF Inhibitors Sales Quantity by Type (2019-2030)
10.2 South America C-MET & HGF Inhibitors Sales Quantity by Application (2019-2030)
10.3 South America C-MET & HGF Inhibitors 麻豆原创 Size by Country
10.3.1 South America C-MET & HGF Inhibitors Sales Quantity by Country (2019-2030)
10.3.2 South America C-MET & HGF Inhibitors Consumption Value by Country (2019-2030)
10.3.3 Brazil 麻豆原创 Size and Forecast (2019-2030)
10.3.4 Argentina 麻豆原创 Size and Forecast (2019-2030)
11 Middle East & Africa
11.1 Middle East & Africa C-MET & HGF Inhibitors Sales Quantity by Type (2019-2030)
11.2 Middle East & Africa C-MET & HGF Inhibitors Sales Quantity by Application (2019-2030)
11.3 Middle East & Africa C-MET & HGF Inhibitors 麻豆原创 Size by Country
11.3.1 Middle East & Africa C-MET & HGF Inhibitors Sales Quantity by Country (2019-2030)
11.3.2 Middle East & Africa C-MET & HGF Inhibitors Consumption Value by Country (2019-2030)
11.3.3 Turkey 麻豆原创 Size and Forecast (2019-2030)
11.3.4 Egypt 麻豆原创 Size and Forecast (2019-2030)
11.3.5 Saudi Arabia 麻豆原创 Size and Forecast (2019-2030)
11.3.6 South Africa 麻豆原创 Size and Forecast (2019-2030)
12 麻豆原创 Dynamics
12.1 C-MET & HGF Inhibitors 麻豆原创 Drivers
12.2 C-MET & HGF Inhibitors 麻豆原创 Restraints
12.3 C-MET & HGF Inhibitors Trends Analysis
12.4 Porters Five Forces Analysis
12.4.1 Threat of New Entrants
12.4.2 Bargaining Power of Suppliers
12.4.3 Bargaining Power of Buyers
12.4.4 Threat of Substitutes
12.4.5 Competitive Rivalry
13 Raw Material and Industry Chain
13.1 Raw Material of C-MET & HGF Inhibitors and Key Manufacturers
13.2 Manufacturing Costs Percentage of C-MET & HGF Inhibitors
13.3 C-MET & HGF Inhibitors Production Process
13.4 Industry Value Chain Analysis
14 Shipments by Distribution Channel
14.1 Sales Channel
14.1.1 Direct to End-User
14.1.2 Distributors
14.2 C-MET & HGF Inhibitors Typical Distributors
14.3 C-MET & HGF Inhibitors Typical Customers
15 Research Findings and Conclusion
16 Appendix
16.1 Methodology
16.2 Research Process and Data Source
16.3 Disclaimer
听
听
*If Applicable.
